657 related articles for article (PubMed ID: 28826074)
1. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
2. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.
Arkenau HT; Barriuso J; Olmos D; Ang JE; de Bono J; Judson I; Kaye S
J Clin Oncol; 2009 Jun; 27(16):2692-6. PubMed ID: 19332724
[TBL] [Abstract][Full Text] [Related]
3. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Minami S; Ihara S; Ikuta S; Komuta K
World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
[TBL] [Abstract][Full Text] [Related]
4. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.
Livingston JA; Hess KR; Naing A; Hong DS; Patel S; Benjamin RS; Ludwig JA; Conley A; Herzog CE; Anderson P; Meric-Bernstam F; Kurzrock R; Subbiah V
Oncotarget; 2016 Sep; 7(39):64421-64430. PubMed ID: 27486883
[TBL] [Abstract][Full Text] [Related]
5. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer.
Minami S; Ihara S; Komuta K
World J Oncol; 2020 Jun; 11(3):98-105. PubMed ID: 32494316
[TBL] [Abstract][Full Text] [Related]
6. The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.
Kumar R; Geuna E; Michalarea V; Guardascione M; Naumann U; Lorente D; Kaye SB; de Bono JS
Br J Cancer; 2015 Mar; 112(7):1157-65. PubMed ID: 25719834
[TBL] [Abstract][Full Text] [Related]
7. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
Sun R; Champiat S; Dercle L; Aspeslagh S; Castanon E; Limkin EJ; Baldini C; Postel-Vinay S; Hollebecque A; Massard C; Ammari S; Deutsch E; Soria JC; Marabelle A; Ferté C
Eur J Cancer; 2017 Oct; 84():202-211. PubMed ID: 28826073
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score.
Li Y; Pan Y; Lin X; Hou J; Hu Z; Xu L; Zhou Z; Zhang Y; Chen M; Hu D
Front Pharmacol; 2021; 12():819985. PubMed ID: 35237150
[No Abstract] [Full Text] [Related]
9. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
[TBL] [Abstract][Full Text] [Related]
10. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Steuer CE; Wu C; Lawson DH; Kudchadkar R; Master VA; El-Rayes B; Ramalingam SS; Owonikoko TK; Harvey RD
BMC Cancer; 2019 Aug; 19(1):857. PubMed ID: 31464611
[TBL] [Abstract][Full Text] [Related]
11. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
[TBL] [Abstract][Full Text] [Related]
13. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
14. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
15. Preoperative neutrophil-to-lymphocyte ratio and plateletto- lymphocyte ratio as new prognostic factors for patients with colorectal cancer.
Mahsuni Sevinc M; Riza Gunduz U; Kinaci E; Armagan Aydin A; Bayrak S; Umar Gursu R; Gunduz S
J BUON; 2016; 21(5):1153-1157. PubMed ID: 27837617
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
17. Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.
Stavraka C; Pinato DJ; Turnbull SJ; Flynn MJ; Forster MD; O'Cathail SM; Babar S; Seckl MJ; Kristeleit RS; Blagden SP
Cancer; 2014 Jan; 120(2):262-70. PubMed ID: 24399418
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
19. Novel immunological and nutritional-based prognostic index for gastric cancer.
Sun KY; Xu JB; Chen SL; Yuan YJ; Wu H; Peng JJ; Chen CQ; Guo P; Hao YT; He YL
World J Gastroenterol; 2015 May; 21(19):5961-71. PubMed ID: 26019461
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
